Author

Lichuang Men

Observed name: Men, Lichuang

ORCID: 0009-0007-5530-7869

Observed ORCID: 0009-0007-5530-7869

OpenAlex ID: A5080980717

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

2022 · Qian Jiang, Zongru Li, et al. · Journal of Hematology & Oncology · 101

Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

2023 · Sikander Ailawadhi, Zi Chen, et al. · Clinical Cancer Research · 42

First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors

2023 · Nehal J. Lakhani, Drew Rasco, et al. · Clinical Cancer Research · 26

Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma.

2024 · Haibo Qiu, Zhi-wei Zhou, et al. · Journal of Clinical Oncology · 13

Patient‐reported outcomes in adults with tyrosine kinase inhibitor‐resistant chronic myeloid leukemia receiving olverembatinib therapy

2024 · Lu Yu, Weiming Li, et al. · Cancer · 7

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

2022 · Qian Jiang, Zongru Li, et al. · Journal of Hematology & Oncology · 6

Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)–resistant succinate dehydrogenase (SDH)–deficient gastrointestinal stromal tumor (GIST).

2023 · Haibo Qiu, Zhi-wei Zhou, et al. · Journal of Clinical Oncology · 5

Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers

2024 · Hengbang Wang, Yun Yang, et al. · Clinical and Translational Science · 4

Results of POLARIS-1, a global Phase 3 study (Part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)

2025 · Suning Chen, Yu WU, et al. · Blood · 3

Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)

2024 · Huafeng Wang, Xudong Wei, et al. · Blood · 3

Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results

2023 · Junyuan Qi, Xudong Wei, et al. · Blood · 2

Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC) resistant to second-generation ALK inhibitors.

2024 · Yuxiang Ma, Hongyun Zhao, et al. · Journal of Clinical Oncology · 1

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

2023 · Qian Jiang, Zongru Li, et al. · Journal of Hematology & Oncology · 1

Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

2025 · Sikander Ailawadhi, Zi Chen, et al.

Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

2025 · Sikander Ailawadhi, Zi Chen, et al.

Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

2025 · Sikander Ailawadhi, Zi Chen, et al.

Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

2024 · Sikander Ailawadhi, Zi Chen, et al.

Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

2024 · Sikander Ailawadhi, Zi Chen, et al.

Data from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

2024 · Sikander Ailawadhi, Zi Chen, et al.

Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

2024 · Sikander Ailawadhi, Zi Chen, et al.

Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

2024 · Sikander Ailawadhi, Zi Chen, et al.

Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

2024 · Sikander Ailawadhi, Zi Chen, et al.

Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

2024 · Sikander Ailawadhi, Zi Chen, et al.

Data from First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors

2024 · Nehal J. Lakhani, Drew Rasco, et al.

Supplementary Data 1 from First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors

2024 · Nehal J. Lakhani, Drew Rasco, et al.

Works count: 45

Citation count: 214

H-index: 6

I10-index: 4